Xiaoguang Dou

Dr. Xiaoguang Dou

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
YLYanwei Li
Yanwei Li
QSQiuju Sheng
Qiuju Sheng
CZChong Zhang
Chong Zhang
CHChao Han
Chao Han
HBHai Bai
Hai Bai
XDXiaoguang Dou
Xiaoguang Dou

1 April 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
JWJie Wang
Jie Wang
QSQiuju Sheng
Qiuju Sheng
YDYang Ding
Yang Ding
RCRan Chen
Ran Chen
XSXiaofeng Sun
Xiaofeng Sun
FLFengmin Lu
Fengmin Lu

22 June 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
RFRong Fan
Rong Fan
JNJunqi Niu
Junqi Niu
HMHong Ma
Hong Ma
QXQing Xie
Qing Xie
JCJun Cheng
Jun Cheng
CCChronic Hepatitis B Study Consortium
Chronic Hepatitis B Study Consortium

24 August 2012 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
HBHan Bai
Han Bai
XCXiaokai Chen
Xiaokai Chen
LZLin Zhang
Lin Zhang
XDXiaoguang Dou
Xiaoguang Dou
Background: Chronic pancreatitis is characterized by progressive fibrosis, pain and loss of exocrine and endocrine functions. The long-standing chronic pancreatitis and its associated pancreatic fibrosis are the most common pathogenic events involved in human pancreatic carcinogenesis, but the therapeutic strategies to chronic pancreatitis and the chemoprevention of pancreatic carcinogenesis are very limited.Methods: We investigated the effect of sulindac, a non-steroidal anti-inflammatory drug (NSAID), on inhibition of chronic pancreatitis in a caerulein induced chronic pancreatitis mouse model.Results: Sulindac significantly reduced the severity of chronic pancreatitis including the extent of acini loss, inflammatory cell infiltration and stromal fibrosis. The protein expression of phosphorylation of MEK/ERK was inhibited in the chronic pancreatic tissues by sulindac treatment as measured by Western blot assay. The levels of inflammatory cytokines including TNF-α and MCP-1 were also significantly decreased with sulindac treatment, as well as the expression of TGF-β, PDGF-β, SHH and Gli in the chronic pancreatic tissue detected by qPCR assay and confirmed by western blot assay. The activation of pancreatic satellet cells was also inhibited by sulindac as measured by the activity of α-smooth muscle actin (α-SMA) in the pancreatic tissue of chronic pancreatitis.Conclusions: Sulindac is a promising reagent for the treatment of chronic pancreatitis via inhibition of inflammatory cell infiltration and stromal fibrosis, the inhibitory effect of sulindac on chronic pancreatitis may through targeting the activation ERK/MAPK signaling pathway.

20 June 2024 in Gut
Verified
Journal Article
Closed access
PDF file
RFRong Fan
Rong Fan
SZSiru Zhao
Siru Zhao
JNJunqi Niu
Junqi Niu
HMHong Ma
Hong Ma
QXQing Xie
Qing Xie
JHJinlin Hou
Jinlin Hou
Objective: Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis B (CHB) but this rarely occurs with currently approved therapies. We aimed to develop and validate a prognostic model for HBsAg loss on treatment using longitudinal data from a large, prospectively followed, nationwide cohort. Design: CHB patients receiving nucleos(t)ide analogues as antiviral treatment were enrolled from 50 centres in China. Quantitative HBsAg (qHBsAg) testing was prospectively performed biannually per protocol. Longitudinal discriminant analysis algorithm was used to estimate the incidence of HBsAg loss, by integrating clinical data of each patient collected during follow-up. Results: In total, 6792 CHB patients who had initiated antiviral treatment 41.3 (IQR 7.6–107.6) months before enrolment and had median qHBsAg 2.9 (IQR 2.3–3.3) log 10 IU/mL at entry were analysed. With a median follow-up of 65.6 (IQR 51.5–84.7) months, the 5-year cumulative incidence of HBsAg loss was 2.4%. A prediction model integrating all qHBsAg values of each patient during follow-up, designated GOLDEN model, was developed and validated. The AUCs of GOLDEN model were 0.981 (95% CI 0.974 to 0.987) and 0.979 (95% CI 0.974 to 0.983) in the training and external validation sets, respectively, and were significantly better than those of a single qHBsAg measurement. GOLDEN model identified 8.5%–10.4% of patients with a high probability of HBsAg loss (5-year cumulative incidence: 17.0%–29.1%) and was able to exclude 89.6%–91.5% of patients whose incidence of HBsAg loss is 0. Moreover, the GOLDEN model consistently showed excellent performance among various subgroups. Conclusion: The novel GOLDEN model, based on longitudinal qHBsAg data, accurately predicts HBsAg clearance, provides reliable estimates of functional hepatitis B virus (HBV) cure and may have the potential to stratify different subsets of patients for novel anti-HBV therapies.

21 June 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
ZLZhihua Liu
Zhihua Liu
ZCZhongdan Chen
Zhongdan Chen
FCFuqiang Cui
Fuqiang Cui
YDYang Ding
Yang Ding
YGYunfei Gao
Yunfei Gao
JHJinlin Hou
Jinlin Hou
The World Health Organization (WHO) has set the goal of eliminating hepatitis as a threat to public health by 2030. Blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is not only the key to eliminating viral hepatitis, but also a hot issue in the field of hepatitis B prevention and treatment. To standardize the clinical management of preventing MTCT of HBV and achieve zero HBV infection among infants, the Chinese Foundation for Hepatitis Prevention and Control organized experts to compile a management algorithm for prevention of MTCT of HBV based on the latest research progress and guidelines, including 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core components.